Pharmacogenomics of anti-TB drugs-related hepatotoxicity

Pharmacogenomics

Volumn 9, Issue 3, 2008, Pages 311-321

  Roy, Puspita Das ^a   Majumder, Mousumi ^a   Roy, Bidyut ^a  

^a INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

Antituberculosis drugs; Hepatotoxicity; Isoniazid; Pharmacogenomics

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 REDUCTASE; ETHAMBUTOL; GLUTATHIONE TRANSFERASE M1; HLA DR2 ANTIGEN; ISONIAZID; MANGANESE SUPEROXIDE DISMUTASE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; CYTOCHROME P450 2E1; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACETYLATOR PHENOTYPE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG ACETYLATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MONOTHERAPY; NAUSEA; PHARMACOGENOMICS; POPULATION GENETICS; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; URIC ACID BLOOD LEVEL; VISUAL DISORDER; VOMITING; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; INCIDENCE; LIVER; MALARIA; PATHOLOGY; PHARMACOGENETICS;

ANTITUBERCULAR AGENTS; CYTOCHROME P-450 CYP2E1; DRUG THERAPY, COMBINATION; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; LIVER; MALARIA; PHARMACOGENETICS;

EID: 42449142373     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.3.311     Document Type: Review

References (66)

1. Farrell GC: Drug-induced acute hepatitis. In: Drug-induced liver disease Farrell GG (Ed.). Churchill Livingstone. Edinburgh, UK, 247-299 (1994)
2. Pessayre D, Larrey D: Drug-induced liver injury: In: Oxford Textbook of clinical Hepatolohy Volume 2. McIntyre N, Benhamou JP, Bircher J, Rizetto M, Rodes J (Eds) Oxford University Press Oxford, UK (1991)
3. Sim E, Payton M, Noble M, Minchin R: An update on genetic, structural and functional studies on arylamine N-acetyltransferases in eucaryotes and procaryotes, Hum. Mol. Genet. 9, 2435-2441(2000).
4. Nebert DW: Polymorphism in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271 (1997).
5. Mitchel JR, Thorgeirsson UP, Black M et al.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin. Pharmatol. Ther. 18, 70-79 (1975).
6. Yamamoto T, Suou T, Hirayama C: Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology6, 295-298 (1986).
7. Mitchell JR, Zimmerman HJ, Ishak KG et al.: Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann. Intern. Med. 84, 181-192 (1976).
8. Gurumurthy F, Krishnamurthy MS, Nazareth O et al.: Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am. Rev. Respir. Dis. 129, 58-61 (1984).
9. Singh J, Garg PK, Thakur VS, Tandon RK: Antituberculosis treatment induced hopatotoxicity: Does acetylation status matter? Indian. J. Physiol. Pharmacol. 39, 43-46 (1995)
10. Benichou C: Criteria of drug induced liver disorder: report of an International Consensus Meeting. J. Hepatol. 11, 272-276 (1990).
11. Rapp RS, Campbell RW, Howell JC, Kendig ELJ: Isoniazid hepatotoxicity in children. Am. Rev. Respir. Dis. 118, 794-796 (1978).
12. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK: Risk Factors for hepatotoxicity from antituberculous drugs: a case control study. Thorax 51, 132-136 (1996).
13. Kopanoff DE, Snider D, Caras G: Isoniazid related hepatitis: a U.S. Public Health Service cooperative Surveillance study. Am. Rev. Respir. Dis. 117, 991-1001 (1979).
14. Wong WM, Wu PC, Yuen MF et al.: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31, 201-206 (2000).
15. Ungo JR, Jones D, Ashkin D et al.: Antituberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 157, 1871-1876 (1998).
16. Girling DJ: The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 59, 13-32 (1978).
17. Bachs L, Pares A, Elena M, Piera C, Rodes J: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102, 2077-2080 (1992).
18. Pessayre D, Bentata M, Deggott C et al.: Isoniazid rifampicin fulminant hepatitis: a possible consequence of enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 72, 284-289 (1977).
19. Lees AW, Allen GW, Smith J, Tyrrell WF, Fallon RJ: Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 52, 182-190 (1971).
20. Fountain FF, Tolley E, Chrisman CR, Self TH: Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128, 116-123 (2005).
21. Saukkonen JJ, Cohn DL, Jasmer RM et al.: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 174, 935-952 (2006).
22. Garg PK, Tandon RK: Antituberculous Agents Induced Liver Injury. In: Drug-induced Liver Disease. Kaplowitz N, Deleve LD (Eds). Marcel Dekker, New York, USA. (2003).
23. Thompson NP, Caplin ME, Hamilton MI et al.: Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur. Respir. J. 8, 1384-1388 (1995).
24. Singh J, Garg PK, Tandon RK: Hepatotoxicity due to antituberculosis therapy: clinical profile and reintroduction of therapy. J. Clin. Gastroenterol. 22, 211-214 (1996).
25. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB: Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 193, 901-903 (1976).
26. Lauterburg BH, Smith CV, Todd EL, Mitchel JR: Oxidation of hydrazine metabolites formed from isoniazid. Clin. Pharmacol. Ther. 38, 566-571 (1985).
27. Sarma GR, Immanuel, C, Kailasam S, Narayana AS, Venkatesan P: Rifampicin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampicin. Am. Rev. Respir. Dis. 133, 1072-1075 (1986).
28. Payton M, Auty R, Delgoda R, Everett M, Sim E: Cloning and characterization arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased expression results in isoniazid resistance. J. Bacteriol. 181, 1343-1347 (1999).
29. Upton AM, Mushtaq A, Victor TC et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. 42, 309-317 (2001).
30. Majumder M, Sikdar N, Ghosh S, Roy B: Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int. J. Cancer 120, 2148-2156 (2007).
31. Golka K, Blaszkewicz M, Samimi M, Bolt HM, Selinski S: Reconstruction of N-acetyltransferase 2 haplotypes using PHASE. Arch. Toxicol. (2007) (Epub ahead of print).
32. Batra J, Sharma SK, Ghosh B: Arylamine N-acetyl transferase gene polymorphisms markers for atopic asthma serum IgE and blood eosinophil counts. Pharmacogenomics 7, 673-682 (2006).
33. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM: N-acetyltranferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22, 1993-1999 (2001).
34. Morita S, Yano M, Tsujinaka T et al.: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous carcinoma. Int. J. Cancer 80, 685-688 (1999).
35. Ohno M, Yamaguchi I, Yamamoto I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4, 256-261 (2000).
36. Huang YS, Chern HD, Su WJ et al.: Polymorphisms of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35, 883-889 (2002).
37. Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb.) 87(6), 551-556 (2007).
38. Roy B, Chowdhury A, Kundu S et al.: Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Castroenterol. Hepatol. 16, 1033-1037 (2001).
39. Vuilleumier N, Rossier MF, Chiappe A et al.: CYP2E1 genotype and isoniazid-induced hepatotoxicity irmpatients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 62, 423-429 (2006).
40. Watkins PB: The role of cytochrome P450s in drug-induced liver disease. In: Drug-induced liver disease Kaplowitz N, Deleve LD (Eds). Marcel Dekker, New York, USA 15-33, (2003).
41. Yue J, Peng RX, Yang J, Kong R, Liu J: CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol. Sin. 25, 699-704 (2004).
42. Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37, 924-930 (2003).
43. Watanabe J, Hayashi S, Kawajiri K et al.: Different regulation and expression of the human CYP2E1 gene due to the Rsa 1 polymorphism in the 5′ flanking region. J. Biochem 116, 321-326 (1994).
44. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, Waziers ID: Human cytochrome P4502E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6, 203-211 (1996).
45. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park BK: Expression of cytochrome P4502E1 (CYP2E1) in human liver: assessment on mRNA genotype and phenotype. Pharmacogenetics 8, 411-421 (1998).
46. Le Marchand L, Sivaraman L, Pierce L et al.: Association of CYP1A1, GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 58, 4858-4863 (1998).
47. Sikdar S, Mahmud SKA, Paul RR, Roy B: Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett., 195, 33-42 (2003).
48. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S: Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. 21, 781-786 (2006).
49. Strange RC, Jones PW, Fryer AA: Glutathione S-transferase: genetics and role in toxicology. Toxicol. Lett. 112-113, 357-363 (2000).
50. Simon T, Becquemont L, Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67(4), 432-437 (2000).
51. Huang YS, Su WJ, Huang YH et al.: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. 47, 128-134 (2007).
52. Pemble S, Schroeder KR, Spencer SR et al.: Human glutathione-S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300, 271-276 (1994).
53. Sikdar N, Paul RR, Roy B: Glutathione S transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int. J. Cancer. 109, 95-101 (2004).
54. Rebbeck T, Walker A, Jaffe J, White DL, Wein AJ, Malkowicz SB: Glutathione-S-transferase μ (GSTM1) and theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9, 283-287 (1999).
55. Cotton S, Sharp L, Little J, Brockton N: Glutathione-S-transferase polymorphisms and colorectal cancer: HuGE review. Am. J. Epidemiol. 151, 7-32 (2000).
56. Geisler SA, Olshan AF: GSTM1, GSTT1 and risk of squamous cell carcinoma of head and neck: a mini-HuGE review, Am. J. Epidemiol. 154, 95-105 (2001).
57. Roy B, Majumder PP, Dey B et al.: Ethnic differences in distributions of GSTM1 and GSTT1 homozygous "null" genotypes in India. Hum. Biol. 73, 443-450 (2001).
58. Lee EJ, Wong JY, Yeoh PN, Gong NH: Glutathione S-transferase-theta (GSTT1) genetic polymorphism among Chinese. Malays and Indians in Singapore. Pharmacogenetics 5, 332-334 (1995).
59. Sodhi CP, Rana SV, Mehta SK et al.: Study of oxidative stress in isoniazid induced hepatic injury in young rats with and without protein energy malnutrition. J. Biochem. Toxicol. 11, 139-146 (1996).
60. Sodhi CP, Rana SV, Mehra S, Vaiphei K, Goel RC, Mehta SK: Study of oxidative stress in rifampicin induced hepatic injury in young rats with and without protein energy malnutrition. Hum. Exp. Toxicol. 16, 315-321 (1997).
61. Chowdhury A, Santra A, Kundu S et al.: Induction of oxidative stress in antitubercular drug-induced hepatotoxicity. Indian J. Gastroenterol. 20, 97-100 (2001).
62. Mehra NK, Taneja V, Chaudhuri TK et al.: Pulmonary tuberculosis In: HLA in Asia-Oceania-1986. Aizawa M (Ed.). Hokkaido University Press, Sapporo, Japan, 374-379 (1986).
63. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166, 916-919 (2002).
64. Agundez JAG, Martinez C, Garcia-Martin E: Analyses of linkage disequilibrium of seven NAT2 SNPs in 2,068 genes form Caucasians: Three SNPs are enough to predict 99.4% of slow acetylation genes. Fourth International workshop on the Arylamine N-acetyltransferases, Alexandroupolis, Greece, 14-16 September (2007).
65. Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 23, 381-387 (2002).
66. Westwood IM, Bhakta S, Russell AJ et al.: Small molecule inhibitors of arylamine N-acetyltransferase (NAT) in Mycobacterium tuberculosis mimic deletion of the nat gene: support for a novel anti-tubercular target. Fourth International workshop on the Arylamine Nacetyltransferases, Alexandroupolis, Greece, 14-16 September (2007).